Tyme Technologies Prices $12 Million Registered Offering

3/31/19

NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME) announced today that it has priced a registered offering of 8 million shares of its common stock, par value $0.0001 per share, and warrants to purchase 8 million shares of its common stock at a combined purchase price of $1.50 per share of common stock and accompanying warrant, resulting in gross proceeds of approximately $12 million. The warrants will be exercisable beginning six months after issuance at a price of $2.00 per share of common stock and have a term of five years commencing on the date of issuance. The shares of common stock and the warrants will be immediately separable and will be issued separately. The offering is expected to close on April 2, 2019, subject to customary closing conditions.

The company intends to use the net proceeds from the offering to continue the development of its clinical and preclinical assets as well as for general corporate purposes including, but not limited to, increasing working capital, general and administrative expenses, and other business opportunities.

Canaccord Genuity LLC is acting as sole book-running manager for the offering. H.C. Wainwright & Co., LLC is acting as lead manager for the offering.

About Tyme Technologies

Tyme Technologies, Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.